Vicore Pharma Holding AB (publ) (VICO.ST) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Sweden · ISIN SE0007577895

Price
9.90 SEK
Market cap
2.79 bn SEK
P/E (2025)
–
P/S (2025)
730.49
Dividend yield
0.00 %
Net margin
-12,509.14 %
Return on equity (ROE)
-43.59 %
Return on assets (ROA)
-39.15 %

Vicore Pharma Holding AB (publ) financials

Fiscal year20242025
Revenue109.35 m SEK3.82 m SEK
Gross profit109.35 m SEK3.82 m SEK
Operating income-194.19 m SEK-454.45 m SEK
EBIT-168.88 m SEK-477.41 m SEK
Net income-168.63 m SEK-477.47 m SEK
Diluted EPS – continuing operations-0.75 SEK-1.99 SEK

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Vicore Pharma Holding AB (publ)

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.